Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021
July 08 2021 - 7:00AM
Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company
focused on developing therapies targeting key signaling pathways
that drive the formation and spread of cancer, today announced that
Dr. Mark Manfredi, CEO of Ikena Oncology, will participate in a
panel discussing next-generation approaches to targeted oncology at
the upcoming virtual William Blair Biotech Focus Conference.
Details on the panel webcast can be found below.
Date: Thursday,
July 15, 2021 Time:
9:00 – 9:45 a.m.
ET Webcast Link:
Register
The panel will be webcast live and can be
accessed by visiting the Investors & Media section of the
company’s website at www.ikenaoncology.com. The webcast will be
archived for a period of 30 days following the conclusion of the
live event.
About Ikena Oncology
Ikena Oncology is a targeted oncology company
focused on developing cancer therapies targeting key signaling
pathways that drive the formation and spread of cancer. Ikena is
advancing five programs that include four product candidates in
either clinical development or IND-enabling studies: IK-930, a TEAD
inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor
program targeting the KRAS signaling pathway; IK-175, an AHR
antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an
EP4 receptor antagonist. Ikena has entered into a global strategic
collaboration with Bristol-Myers Squibb Company for its IK-175 and
IK-412 programs. To learn more visit www.ikenaoncology.com or
follow us on Twitter and LinkedIn.
Media Contact:Gwen SchankerLifeSci
Communicationsgschanker@lifescicomms.comInvestor
Contact:Rebecca CohenIkena
Oncologyrcohen@ikenaoncology.com
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Apr 2023 to Apr 2024